Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Open Access

Table S6 from NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in NF1-Mutant Melanoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MIMilad IbrahimIIIrineu Illa-BochacaGJGeorge Jour

Discussion

Loading...

Member takes

Overview

Observational analysis reveals EGFR activation improves treatment outcomes in NF1-mutant melanoma patients, suggesting better management strategies are needed.

Key Points

  • NF1 loss promotes EGFR activation, enhancing sensitivity to EGFR inhibition in melanoma.
  • Patients with NF1 mutations showed improved responses to EGFR-targeted treatments.
  • Analysis of clinical characteristics highlights important factors in patient response to EGFR inhibition.
  • The findings suggest a new potential route for melanoma treatment by targeting EGFR pathways.

Cite This Study

Ibrahim et al. (2025) studied this question.

synapsesocial.com/papers/68c23a2cb210217d6477fb87https://doi.org/10.1158/0008-5472.30029855
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Table S7 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025
  2. 2Tables S1 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025
  3. 3Table S2 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025
  4. 4Figure S2 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025
  5. 5Figure S5 from <i>NF1</i> Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in <i>NF1</i>-Mutant Melanoma2025